Pacific Edge is a cancer diagnostics company. We specialise in discovering, building and commercialising innovative cancer diagnostic tests that can contribute to a clinically meaningful difference in the detection and management of cancer
Our products are built from our proprietary genetic databases, which are used to identify diagnostic and prognostic biomarkers for cancer.
Our intellectual property covers the areas of bladder, gastric, colorectal and endometrial cancers and melanoma; however, our commercial focus is on bladder cancer products for the short to medium term. Our wider portfolio is expected to provide us with further options in the future.
Cxbladder is a new class of bladder cancer detection and management tests, which are non-invasive, highly effective and more accurate than other urine-based cancer tests.
Cxbladder offers a step change in how bladder cancer is detected and monitored, and we are building a suite of Cxbladder tests to meet different clinical needs.
Our Business Model
We operate a franchise-like business model, which includes our wholly owned subsidiaries and other licensed partners.
We have targeted specific geographies and markets where we expect our products can be readily adopted at scale.
Pacific Edge has certified laboratories in New Zealand and in the United States.
Both laboratories hold a Certificate of Compliance from the Center for Medicare & Medicaid Services (CMS) for Clinical Laboratory Improvement Amendments (CLIA), which sets the standards for clinical laboratory testing in the United States.
This compliance enables Pacific Edge's laboratories to provide commercial services to clinicians and process urine samples from patients in the United States for Cxbladder.